Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell ...
The majority of the work happening in cell therapy falls into these two buckets. But not all of it. A handful of biotechs are asking a next-generation question: What if we could modify a patient ...
today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This ...
In recent years, we have observed a revolution in taxonomy and diagnosis of human diseases due to the advent of the next-generation sequencing technology. Long lists of potential disease ... This ...
today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration ...